Cargando…
Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety
COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650610/ https://www.ncbi.nlm.nih.gov/pubmed/19281071 |
_version_ | 1782165098467426304 |
---|---|
author | Rossi, Andrea Khirani, Sonia Cazzola, Mario |
author_facet | Rossi, Andrea Khirani, Sonia Cazzola, Mario |
author_sort | Rossi, Andrea |
collection | PubMed |
description | COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting β(2)-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome. |
format | Text |
id | pubmed-2650610 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-26506102009-05-04 Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety Rossi, Andrea Khirani, Sonia Cazzola, Mario Int J Chron Obstruct Pulmon Dis Reviews COPD is characterized by progressive airflow obstruction which does not fully reverse to inhaled or oral pharmacotherapy. The management of patients with COPD has taken a totally new direction over the past 20 years, thank to the use of novel therapies aimed to improve and modify the natural history of COPD. Long-acting bronchodilators, including long-acting β(2)-agonists (LABAs), were introduced several years ago in order to enhance improvements in lung function, health status related quality of life, and reduce the rate of exacerbations. These effects can be boosted by the combination of LABAs with long-acting anticholinergic, and/or with inhaled corticosteroids. Inhaled LABAs are commonly well tolerated although adverse effects such as tremor and palpitations are occasionally troublesome. Dove Medical Press 2008-12 2008-12 /pmc/articles/PMC2650610/ /pubmed/19281071 Text en © 2008 Dove Medical Press Limited. All rights reserved |
spellingShingle | Reviews Rossi, Andrea Khirani, Sonia Cazzola, Mario Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
title | Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
title_full | Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
title_fullStr | Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
title_full_unstemmed | Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
title_short | Long-acting β(2)-agonists (LABA) in chronic obstructive pulmonary disease: efficacy and safety |
title_sort | long-acting β(2)-agonists (laba) in chronic obstructive pulmonary disease: efficacy and safety |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2650610/ https://www.ncbi.nlm.nih.gov/pubmed/19281071 |
work_keys_str_mv | AT rossiandrea longactingb2agonistslabainchronicobstructivepulmonarydiseaseefficacyandsafety AT khiranisonia longactingb2agonistslabainchronicobstructivepulmonarydiseaseefficacyandsafety AT cazzolamario longactingb2agonistslabainchronicobstructivepulmonarydiseaseefficacyandsafety |